LVAD Companies Address Thrombosis Fears Raised In NEJM Report
This article was originally published in The Gray Sheet
The CEOs of Thoratec and HeartWare addressed the recent highly publicized report on the risk of LVAD thrombosis at the J.P. Morgan Healthcare Conference.
You may also be interested in...
A new refuse-to-accept guidance; FDA finalizes classification decisions; and the agency awards an emergency authorization for a new rapid Ebola assay.
Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
Thoratec says that the recent article in the New England Journal of Medicine describing surprisingly high rates of pump thrombosis in left-ventricular assist devices may have short-term sales implications, but they will minimize over time. The company says it is working with clinical centers on best practices to avoid thrombosis.